

78
NRP

Covid-19
National Research Programme

FNSNF

SWISS NATIONAL SCIENCE FOUNDATION

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: a randomized, parallel-group, open-label, multi-center pilot trial.

The **PROTECT-COVID-19** Study


Dienstagsclub Infektiologie
29.06.2021

PD Dr. med. Michael Osthoff
Division of Internal Medicine
University Hospital Basel




01

Introduction



The complement cascade



Role of complement in many diseases

Dysregulation

PNH
aHUS and TTP
Transplant rejection
....

Autoimmune

Lupus nephritis
Guillain-Barré Syndrome
IgA nephropathy
-

Inflammatory

Macular degeneration
ANCA-associated vasculitis
Atherosclerosis
Sepsis
....

Ischemia-reperfusion

Myocardial infarction
Stroke
....

Acute injuries

Trauma
Hemodialysis
....